Has bilateral sacroiliitis Grade 2 or unilateral sacroiliitis Grade 3 or Grade 4
Is a nursing or pregnant female, or intends to become pregnant within 6 months after receiving trial medication
Intends to donate eggs (female participants) or sperm (male participants) while receiving trial medication or within 6 months after trial medication
Has any clinically significant condition or situation that would interfere with the trial evaluations or participation in the trial
Has ever received any cytotoxic drugs, including chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents
• Disease-modifying anti-rheumatic drugs (30 days off drug)
• Live vaccinations (3 months off drug)
• Investigational medications (30 days or 5 half-lives off drug, whichever is longer)
• Bacille Calmette-Guerin (BCG) vaccination (12 months off drug)
Has any systemic inflammatory condition, including psoriatic arthritis, active Lyme disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus infection, rheumatoid arthritis, active uveitis, or active IBD
Has a history of latent or active granulomatous infection prior to Screening
Had a nontuberculous mycobacterial infection or opportunistic infection within 6 months prior to Screening
Has a history of an infected joint prosthesis, or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced
Had a serious infection, has been hospitalized for an infection, or has been treated with IV antibiotics for an infection within 2 months prior to Baseline
Had a history of, or ongoing, chronic or recurrent infectious disease
Is known to be infected with human immunodeficiency virus (HIV) or seropositive for hepatitis C virus (HCV)
Has had a chest x-ray within 2 months prior to Screening that shows an abnormality suggestive of a current active infection or malignancy
Has a history of lymphoproliferative disease
Has had a malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured)
Has a history of known demyelinating diseases such as multiple sclerosis or optic neuritis
Has a history of or concurrent congestive heart failure of any grade
Has a transplanted organ (with the exception of a corneal transplant performed >= 3 months prior to baseline)
Has current signs or symptoms of significant medical illness which could interfere with the trial, or require treatment that might interfere with the trial
Is a user of recreational or illicit drugs or has or had a substance abuse (drug or alcohol) problem within the previous 2 years

NCT03253796_exc_T1
Qualifier
bilateral
NCT03253796_exc_T2
Condition
sacroiliitis
NCT03253796_exc_T3
Qualifier
Grade 2
NCT03253796_exc_T4
Qualifier
unilateral
NCT03253796_exc_T5
Condition
sacroiliitis
NCT03253796_exc_T6
Qualifier
Grade 3
NCT03253796_exc_T7
Qualifier
Grade 4
NCT03253796_exc_T8
Scope
Grade 3 or Grade 4
NCT03253796_exc_T9
Condition
nursing
NCT03253796_exc_T10
Condition
pregnant
NCT03253796_exc_T11
Person
female
NCT03253796_exc_T12
Condition
pregnant
NCT03253796_exc_T13
Temporal
within 6 months after receiving trial medication
NCT03253796_exc_T14
Mood
intends to become
NCT03253796_exc_T15
Procedure
donate eggs
NCT03253796_exc_T16
Procedure
nate e erm (
NCT03253796_exc_T17
Person
female
NCT03253796_exc_T18
Person
male
NCT03253796_exc_T19
Temporal
while receiving trial medication
NCT03253796_exc_T20
Temporal
within 6 months after trial medication
NCT03253796_exc_T21
Reference_point
trial medication
NCT03253796_exc_T22
Reference_point
trial medication
NCT03253796_exc_T23
Scope
donate eggs (female participants) or sperm (male participants)
NCT03253796_exc_T24
Scope
while receiving trial medication or within 6 months after trial medication
NCT03253796_exc_T26
Drug
cytotoxic drugs
NCT03253796_exc_T27
Drug
chlorambucil
NCT03253796_exc_T28
Drug
cyclophosphamide
NCT03253796_exc_T29
Drug
nitrogen mustard
NCT03253796_exc_T30
Drug
alkylating agents
NCT03253796_exc_T31
Scope
chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents
NCT03253796_exc_T32
Drug
Disease-modifying anti-rheumatic drugs
NCT03253796_exc_T33
Temporal
30 days off drug
NCT03253796_exc_T34
Drug
Live vaccinations
NCT03253796_exc_T35
Temporal
3 months off drug
NCT03253796_exc_T36
Drug
Investigational medications
NCT03253796_exc_T37
Temporal
 or 5  g, which
NCT03253796_exc_T38
Temporal
5 half-lives off drug
NCT03253796_exc_T39
Scope
30 days or 5 half-lives off drug
NCT03253796_exc_T40
Drug
Bacille Calmette-Guerin (BCG) vaccination
NCT03253796_exc_T41
Temporal
12 months off drug
NCT03253796_exc_T42
Condition
inflammatory condition
NCT03253796_exc_T43
Condition
psoriatic arthritis
NCT03253796_exc_T44
Condition
Lyme disease
NCT03253796_exc_T45
Qualifier
active
NCT03253796_exc_T46
Condition
systemic lupus erythematosus
NCT03253796_exc_T47
Condition
infectious arthritis
NCT03253796_exc_T48
Condition
vasculitis
NCT03253796_exc_T49
Condition
parvovirus infection
NCT03253796_exc_T50
Condition
rheumatoid arthritis
NCT03253796_exc_T51
Condition
active uveitis
NCT03253796_exc_T52
Condition
active IBD
NCT03253796_exc_T53
Scope
psoriatic arthritis, active Lyme disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus infection, rheumatoid arthritis, active uveitis, or active IBD
NCT03253796_exc_T54
Qualifier
active
NCT03253796_exc_T55
Qualifier
latent
NCT03253796_exc_T56
Condition
granulomatous infection
NCT03253796_exc_T57
Temporal
prior to Screening
NCT03253796_exc_T58
Reference_point
Screening
NCT03253796_exc_T59
Scope
latent or active
NCT03253796_exc_T60
Condition
nontuberculous mycobacterial infection
NCT03253796_exc_T61
Condition
opportunistic infection
NCT03253796_exc_T62
Temporal
within 6 months prior to Screening
NCT03253796_exc_T63
Scope
nontuberculous mycobacterial infection or opportunistic infection
NCT03253796_exc_T64
Condition
infected
NCT03253796_exc_T65
Device
joint prosthesis
NCT03253796_exc_T66
Observation
history
NCT03253796_exc_T67
Drug
antibiotics
NCT03253796_exc_T68
Mood
suspected
NCT03253796_exc_T69
Condition
infection
NCT03253796_exc_T70
Device
joint prosthesis
NCT03253796_exc_T71
Condition
serious infection
NCT03253796_exc_T72
Procedure
hospitalized
NCT03253796_exc_T73
Condition
infection
NCT03253796_exc_T74
Drug
IV antibiotics
NCT03253796_exc_T75
Condition
infection
NCT03253796_exc_T76
Temporal
within 2 months prior to Baseline
NCT03253796_exc_T77
Qualifier
recurrent
NCT03253796_exc_T78
Qualifier
chronic
NCT03253796_exc_T79
Temporal
ongoing
NCT03253796_exc_T80
Observation
history
NCT03253796_exc_T81
Scope
history of, or ongoing
NCT03253796_exc_T82
Scope
chronic or recurrent
NCT03253796_exc_T83
Condition
infectious disease
NCT03253796_exc_T84
Condition
human immunodeficiency virus (HIV)
NCT03253796_exc_T85
Condition
seropositive for hepatitis C virus (HCV)
NCT03253796_exc_T86
Procedure
chest x-ray
NCT03253796_exc_T87
Temporal
within 2 months prior to Screening
NCT03253796_exc_T88
Condition
abnormality
NCT03253796_exc_T89
Mood
suggestive
NCT03253796_exc_T90
Temporal
current
NCT03253796_exc_T91
Qualifier
active
NCT03253796_exc_T92
Condition
infection
NCT03253796_exc_T93
Condition
malignancy
NCT03253796_exc_T94
Scope
infection or malignancy
NCT03253796_exc_T95
Condition
lymphoproliferative disease
NCT03253796_exc_T96
Condition
malignancy
NCT03253796_exc_T97
Temporal
within 5 years before screening
NCT03253796_exc_T98
Reference_point
screening
NCT03253796_exc_T99
Reference_point
Screening
NCT03253796_exc_T100
Condition
 cell c skin and carcinoma in
NCT03253796_exc_T101
Condition
basal cell carcinomas of the skin
NCT03253796_exc_T102
Condition
carcinoma in situ
NCT03253796_exc_T103
Qualifier
cervix
NCT03253796_exc_T104
Qualifier
surgically cured
NCT03253796_exc_T105
Procedure
surgically
NCT03253796_exc_T106
Negation
exceptions
NCT03253796_exc_T107
Scope
squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured
NCT03253796_exc_T108
Condition
demyelinating diseases
NCT03253796_exc_T109
Observation
history
NCT03253796_exc_T110
Condition
multiple sclerosis
NCT03253796_exc_T111
Condition
optic neuritis
NCT03253796_exc_T112
Scope
multiple sclerosis or optic neuritis
NCT03253796_exc_T113
Condition
congestive heart failure
NCT03253796_exc_T114
Temporal
concurrent
NCT03253796_exc_T115
Observation
history
NCT03253796_exc_T116
Scope
history of or concurrent
NCT03253796_exc_T117
Procedure
transplanted organ
NCT03253796_exc_T118
Procedure
corneal transplant
NCT03253796_exc_T119
Temporal
>= 3 months prior to baseline
NCT03253796_exc_T120
Negation
exception of
NCT03253796_exc_T121
Condition
medical illness
NCT03253796_exc_T122
Qualifier
significant
NCT03253796_exc_T123
Observation
interfere with the trial
NCT03253796_exc_T124
Mood
require
NCT03253796_exc_T125
Procedure
treatment
NCT03253796_exc_T126
Observation
interfere with the trial
NCT03253796_exc_T127
Scope
interfere with the trial, or require treatment that might interfere with the trial